Antibodies as Crypts of Antiinfective and Antitumor Peptides

Author(s): W. Magliani, S. Conti, R. L.O.R. Cunha, L. R. Travassos, L. Polonelli

Journal Name: Current Medicinal Chemistry

Volume 16 , Issue 18 , 2009

Become EABM
Become Reviewer


Antibodies (Abs), often associated with antimicrobial and antitumor agents, have emerged as an important class of novel drugs for antigen-driven therapeutic purposes in diverse clinical settings, including oncology and infectious diseases. Abs commonly give rise in the treated host to anti-Ab responses, which may induce adverse reactions and limit their therapeutic efficacy. Their modular domain architecture has been exploited to generate alternative reduced formats (Fabs, scFvs, dAbs, minibodies, multibodies), essentially devoid of the Fc region. The presence of complementarity determining regions (CDRs) ensures the maintenance of selective binding to antigens and supports their use for biotechnological and therapeutic applications. Paradigmatic Abs mimicking the wide-spectrum antimicrobial activity of a yeast killer toxin (killer Abs) have revealed the existence of a family of Abs exerting a direct in vitro and/or in vivo microbicidal activity. Based on the variable sequence of an antiidiotypic recombinant killer Ab, CDR-related peptides have been synthesized, engineered by alanine-scanning and selected according to antimicrobial, antiviral and immunomodulatory properties. Irrespective of the native Ab specificity, synthetic CDRs from unrelated murine and human monoclonal Abs, have shown to display differential in vitro, in vivo and/or ex vivo antifungal (Candida albicans), antiviral (HIV-1) and antitumor (melanoma cells) activities. Alanine substitution of single residues of synthetic CDR peptides resulted in further differential increased/unaltered/decreased biological activity. The intriguing potential of Abs as source of antiinfective and antitumor therapeutics will be discussed, in light of recent advances in peptide design, stability and delivery.

Keywords: Antibodies, therapeutic antibodies, microbicidal antibodies, synthetic CDRs, killer peptides, antiinfective peptides, antitumor peptides

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2009
Page: [2305 - 2323]
Pages: 19
DOI: 10.2174/092986709788453104
Price: $65

Article Metrics

PDF: 12